Clinical Trial Update: Effect of Dapagliflozin Plus Low Dose Pioglitazone on Hospitalization Rate in Patients With HF and HFpEF [Phase 3]

View source ↗

Summary

Phase 3 trial update examining dapagliflozin plus low-dose pioglitazone and its effect on hospitalization in heart failure with preserved ejection fraction (HFp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure with Preserved Ejection Fraction

Drugs mentioned

• Dapagliflozin (dapagliflozin)
• PIOGLITAZONE (Pioglitazone)

Snippet

Sponsor: Hamad Medical Corporation | Conditions: Risk Reduction | Phase 3 | Status: UNKNOWN